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Abstract
Background: Approximately 4–25% of patients with early prostate cancer develop
disease recurrence following radical prostatectomy.
Objective: To identify a molecular subgroup of prostate cancers with metastatic poten-
tial at presentation resulting in a high risk of recurrence following radical prostatectomy.
Design, setting, and participants: Unsupervised hierarchical clustering was performed
using gene expression data from 70 primary resections, 31 metastatic lymph nodes, and
25normal prostate samples. Independent assay validationwas performedusing 322 rad-
ical prostatectomy samples from four sites with a mean follow-up of 50.3 [34_TD$DIFF]months.
Outcome measurements and statistical analysis: Molecular subgroups were identiﬁed
using unsupervised hierarchical clustering. A partial least squares approach was used to
generate a gene expression assay. Relationships with outcome (time to biochemical and
metastatic recurrence) were analysed using multivariable Cox regression and log-rank
analysis.
Results and limitations: A molecular subgroup of primary prostate cancer with biology
similar tometastatic disease was identiﬁed. A 70-transcript signature (metastatic assay)
was developed and independently validated in the radical prostatectomy samples.
Metastatic assay[35_TD$DIFF] positive patients had increased risk of biochemical recurrence (multi-
variable hazard ratio [HR] 1.62 [1.13–2.33]; p = 0.0092) and metastatic recurrence
(multivariable HR = 3.20 [1.76–5.80]; p = 0.0001). A combined model with Cancer of
the Prostate Risk Assessment [36_TD$DIFF]post surgical (CAPRA-S) identiﬁed patients at an increased
* Corresponding author. Centre for Cancer Research and Cell Biology, Queen’s University of Belfast,
97 Lisburn Road, Belfast, BT9 7BL, UK.
E-mail address: r.kennedy@qub.ac.uk (R.D. Kennedy).
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1. Introduction
Although prognosis for localised prostate cancer patients
following radical prostatectomy is very good, 4–25%
(dependent upon disease stage and use of population
prostate-specific antigen [PSA] screening) will develop
metastatic diseasewithin 15 [38_TD$DIFF]years [1,2]. In addition, patients
with low- and some intermediate-risk prostate cancers are
best treated by active surveillance; however, there is clinical
uncertainty about progression in this population [3]. Pro-
gression in low/intermediate risk may be due to a more
biologically aggressive genotype of primary tumours, whilst
in clinically higher risk groups there may be undetected
micrometastatic disease at presentation [4]. This could be
treated by adjuvant approaches including pelvic radiothera-
py [5], extended lymph node dissection [6], adjuvant
hormone therapy [7], or chemotherapy [8].
Presently, metastatic risk is estimated from histopatho-
logic grade (Gleason score [GS] and clinical grade grouping),
tumour stage, and presenting PSA level. These prognostic
factors have limitations;15% of lower-grade prostate cancer
patients (Gleason 7) experience disease recurrence [9],
whereas 74–76% of higher-grade patients (Gleason >7)[39_TD$DIFF] do
not develop metastatic disease following surgery [10]. For
Gleason 7 tumours, dominant lesion grade affects prognosis,
40% of Gleason 4 + 3 patients developing recurrence by
5 [38_TD$DIFF]years compared with 15% for Gleason[40_TD$DIFF] 3 + 4 [11]. Clearly,
there is a need to identify additional prognostic factors to
guide adjuvant treatment. Current approaches canbroadly be
classified as mathematical risk models using clinical factors
such as Cancer of the Prostate Risk Assessment (CAPRA) [12]
and CAPRA-surgery (CAPRA-S) [13] scoring, or biomarkers
measured from tumour tissue. Regarding biomarkers,
researchers have taken immunohistochemical approaches
such as high Ki67 expression [14] or PTEN loss to indicate
metastatic potential [15]. Others have used multiplexing
approaches where a gene expression [16–18] or proteomic
signature [19] has been trained against known outcomes to
predict high- and low-risk disease using archived material.
It is recognised that malignancies originating from the
same anatomical site can represent different molecular
entities [20]. We hypothesised that a unique molecular
subgroup of primary prostate cancers may exist that has a
gene expression pattern associated with metastatic disease.
We took an unsupervised hierarchical clustering approach
using primary localised prostate cancer, primary prostate
cancer presenting with concomitant metastatic disease,
lymph node metastasis, and normal prostate samples to
identify a novel ‘‘metastatic subgroup’’. A 70-transcript
signature (metastatic assay) was developed using this
approach and independently validated in a cohort of radical
prostatectomy samples for biochemical and metastatic
recurrence.
2. Patients and methods
2.1. Study design
Study design followed the reporting recommendations for tumour
marker prognostic studies (REMARK) guidelines as outlined in the
criteria checklists (Supplementary Table 1 and Appendix A) and REMARK
study design diagram (Supplementary Fig. 1).
2.2. Patients
Formalin-ﬁxed parafﬁn-embedded (FFPE) sections from 126 samples
(70 primary prostate cancer specimens from radical prostatectomy
resections including those with known concomitant metastases, 31 met-
astatic disease in lymph nodes, and 25 histologically conﬁrmed normal
prostate samples that did not display hypertrophy, sourced from bladder
resections) were collected from the University of Cambridge and the
Institute of Karolinska for molecular subgroup identiﬁcation (Supple-
mentary Table 2). A secondary training dataset of 75 primary resection
sampleswas collected, ofwhich 20were proﬁled in duplicate, to aid in the
selection of the ﬁnal signature length (Supplementary Table 3). For
independent in silico validation, three public datasets were identiﬁed
[17,21,22]: GSE25136 (n = 79; Supplementary Table 4), GSE46691
(n = 545; Supplementary Table 5), and GSE21034 (n = 126; Supplemen-
tary Table 6). A total of 322 FFPE prostatectomy samples from four sites
were collected for independent validation of the assay (Supplementary
Table 7). Biochemical recurrencewasdeﬁned as a [41_TD$DIFF]post-prostatectomy rise
in PSA of>0.2 ng/ml followed by a subsequent rise. Metastatic recurrence
was deﬁned as radiologic evidence of any metastatic disease, including
lymph node, bone, and visceral metastases. Inclusion criteria were T1a–
T3cNXM0prostate cancers treated by radical prostatectomy, no previous
systemic adjuvant or neoadjuvant treatment in [42_TD$DIFF]non-recurrence patients,
and at least 3-yr follow-up. Ethical approval was obtained from East of
England Research Ethics Committee (Ref: 14/EE/1066).
2.3. Metastatic subgroup and assay discovery
The 126 discovery sampleswere analysed for gene expression using a cDNA
microarray platform optimised for FFPE tissue. Unsupervised hierarchical
clustering, an unbiased statistical method to discover structure in data, was
applied to the gene expressionproﬁles. Geneswere selected using variance-
intensity ranking and then an iterative procedure of clustering with
different gene lists to determine the optimal set for reproducibility. Data
matrices were standardised to median gene expression and agglomerative
two-dimensional hierarchical clustering was performed, using Euclidean
risk of biochemical and metastatic recurrence superior to either model alone
(HR = 2.67 [1.90–3.75]; p < 0.0001 and HR = 7.53 [4.13–13.73]; p < 0.0001, respectively).
The retrospective nature of the study is acknowledged as a potential limitation.
Conclusions: The metastatic assay may identify a molecular subgroup of primary prostate
cancers with metastatic potential.
Patient summary: Themetastatic assaymay improve the ability to detect patients at risk of
metastatic recurrence following radical prostatectomy. The impact of adjuvant therapies
should be assessed in this higher-risk population.
# 2017 European Association of Urology. Published by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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distance and Ward’s linkage. The optimal number of sample and gene
clusters were identiﬁed using the GAP statistic [23].
Gene ontology biological processes determined biological signiﬁcance
of the gene clusters. Chi-square or analysis of variance tests were used to
assess association of sample clusters with clinical data. Class labels were
assigned to samples, classifying the subgroup enriched with metastatic
tumours as the ‘‘metastatic-subgroup’’ and the subgroup enriched with
normal prostate samples as the ‘‘[43_TD$DIFF]non-metastatic-subgroup’’.
A signature to identify the metastatic-subgroup was developed using
partial-least-squares (PLS) regression. All model development steps ([44_TD$DIFF]pre-
processing, gene ﬁltering/selection, model parameter estimation) were
nested within 10 5-fold cross validation (CV), including assessment of
signature score reproducibility in 5 separate FFPE sections and
repeatability across 20 resection samples from the secondary training
dataset with technical duplicates. In sum, area under the receiver
operating characteristic curve (AUC), C-index performance for metastatic
recurrence in the additional dataset of 75 resections, and assay stability
across replicates were used to guide the ﬁnal number of transcripts
detected by the assay. Thresholds for dichotomising predictions were
selected at the point where sensitivity and speciﬁcity for detecting the
metastatic subgroup reached a joint maximum.
2.4. Statistical assessment of metastatic assay performance
The performance of the metastatic assay regarding biochemical and
metastatic progression was assessed by sensitivity and speciﬁcity. Cox
regression was used to investigate prognostic effects of the assay with
respect to time to recurrence [45_TD$DIFF]endpoints. The estimated effect of the assay
was adjusted for PSA, age, and GS in a multivariable model. A second
multivariable analysis was performed to investigate the prognostic effect
of the assay when adjusting for CAPRA-S [13], whilst further assessing
additional prognostic effect of a combined model generated for the assay
and CAPRA-S together. Veriﬁcation of proportional hazard assumptions
was assessed using a statistical test based on the Schoenfeld residuals
[24]. Samples with unknown clinical factors were excluded. All tests of
statistical signiﬁcance were two sided at 5% level of signiﬁcance.
2.5. Combined model development and application (metastatic
assay and CAPRA-S)
A combined model using metastatic assay dichotomised calls and
CAPRA-S dichotomised into low risk (CAPRA-S: 0–5) and high risk
(CAPRA-S: 6–10) was assessed in the resection validation cohort
independently against biochemical and metastatic [45_TD$DIFF]endpoints using
Cox regression analysis. Participants were classiﬁed as the ‘‘low risk’’
group given a combined model result of assay negative/CAPRA-S low
risk; otherwise, they were labelled as the ‘‘high risk’’ group (ie, samples
that were classiﬁed as assay negative/CAPRA-S high risk, assay positive/
CAPRA-S low risk, or assay positive/CAPRA-S high risk).
See the Supplementary material for additional experimental detail.
3. Results
3.1. Molecular subtyping and identification of a metastatic
subgroup in the discovery cohort
Wehypothesised that amolecular subgroup of poor prognosis
primary prostate cancerswould be transcriptionally similar to
metastatic disease. To identify this subgroup, we measured
gene expression in primary prostate cancers, primary prostate
cancers with known concomitant metastases, metastatic
lymph node samples, and histologically confirmed normal
prostate tissue (Supplementary Table 2).
Unsupervised hierarchical clustering identified two sam-
ple groups and twogene clusters (Fig. 1A). Importantly, oneof
the molecular subgroups (C1) demonstrated significant
enrichment for primary cancers with known concomitant
metastatic disease (Fig. 1A and 1B, chi-square p< 0.0001). In
addition, the C1 group contained all metastatic lymph node
samples and no normal prostate samples. We defined this
subgroup as the ‘‘metastatic subgroup’’ and the other (C2) as
the ‘‘[43_TD$DIFF]non-metastatic subgroup’’.
3.2. Identifying metastatic-subgroup biology
A feature of the metastatic subgroup was loss of gene
expression observed in gene cluster 1 (G1) (Fig. 1A and
Supplementary Table 8). To investigatewhether loss of gene
expression was due to epigenetic silencing, we measured
DNA methylation in eight metastatic- and 14 [43_TD$DIFF]non-
metastatic-subgroup samples (Supplementary Table 9).
[46_TD$DIFF]Semi-supervised hierarchical clustering of the methylation
data of downregulated genes (G1) separated the samples
into two groups (Supplementary Fig. 2 and Supplementary
Table 10), with 7/8 samples (88%) from the metastatic
subgroup (M2) and 10/14 samples (71%) from the
nonmetastatic subgroup clustering together (M1) (chi-
square, p = 0.02). Functional analysis demonstrated that the
metastatic subgroup had higher levels of methylation in
genes that negatively regulate pathways known to be
involved in aggressive prostate cancer such as WNT and
growth signalling (Supplementary Table 11) [25]. Together
these data suggest that epigenetic silencing is a feature of
the metastatic subgroup and may therefore be important in
metastases.
To better understand themolecular processes upregulated
in the metastatic subgroup, we performed differential gene
analysis, identifying 222[47_TD$DIFF] genes that were overexpressed.
Ingenuity Pathway Analysis (www.ingenuity.com) identified
two upregulated pathways in the metastatic subgroup[48_TD$DIFF] (False
Discovery Rate (FDR[49_TD$DIFF]) p< 0.05). The ToppGene Suite [26]
identified 18 upregulated pathways (FDR p< 0.05) (Supple-
mentary Table 12). These pathways represented mitotic
progression and Forkhead Box M1 (FOXM1) pathways.
Consistently, FOXM1 was 2.80-fold overexpressed in the
metastatic subgroup.
3.3. Development of a metastatic assay
Next, we developed an assay that could identify metastatic-
subgroup tumours (Supplementary Fig. 3). Computational
classification using PLS regression resulted in a 70-transcript
metastatic assay. In the training set, the AUC under CV for
detecting the metastatic-subgroup was 99.1 (98.5–99.8).
The standard deviation (SD) in assay scores using five
separate sections from the same tumour was 0.06,
representing 6.9% of the assay range and 100% agreement
in assay call. In a secondary training dataset of 75 primary
resections, the C-index for detecting the metastatic sub-
group was 90.4, with an SD in assay scores using 20 patient
samples with technical replicates of 0.02 representing 2.9%
of assay range (Supplementary Fig. 4).
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Importantly, as the assay was trained against a distinct
molecular subgroup rather than clinical outcome, there was
a bimodal distribution of scores (Supplementary Fig. 5). The
metastatic assay gene list and weightings are listed in
Supplementary Table 13.
3.4. Metastatic assay performance in public datasets
The assay was applied to three independent public prostate
cancer resection gene expression datasets. Assay scores
were calculated using the PLS model and dichotomised into
[(Fig._1)TD$FIG]
Fig. 1 – Molecular subtyping and identification of the metastatic subgroup. (A) Hierarchical clustering of transcriptional profiles from the discovery
cohort. Specific genes that are upregulated (red) or downregulated (green) are labelled on the vertical axis within gene clusters. Sample cluster C1
represents the ‘‘metastatic subgroup’’ characterised by a shutdown of gene expression (G1) compared with sample cluster C2. (B) Bar chart
representing the number and type of each tumour mapping to each of the two identified sample clusters within the discovery cohort.
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assay positive and assay negative. In the first (n = 79) [21],
the assay was significantly associated with biochemical
recurrencewith a sensitivity of 70.3% and specificity of 66.7%
(chi-square p = 0.0049). In a second (n = 545) [17], the assay
was significantly associatedwithmetastatic [8_TD$DIFF]recurrencewith
a sensitivity of 67.0% and specificity of 54.6% (chi-square
p < 0.0001) (Supplementary Table 14). Using a third dataset
with time to event data (n = 126) [22], multivariable analysis
adjusting for Gleason (grades represented in four sub-
groups), age, and PSA demonstrated an increased risk of
biochemical recurrence (hazard ratio [HR] = 3.03 [1.43–
6.41]; p = 0.0040; Table 1 and Fig. 2A). However, possibly
due to the small number of metastatic events (11%), the
association with outcome in multivariable analysis did not
reach statistical significance (HR = 2.53 [0.67–9.54];
p = 0.1735; Table 1 and Fig. 2B).
3.5. Metastatic assay performance in an independent primary
prostate cancer resection dataset
The assay was then applied to 322 FFPE prostatectomy
samples from four clinical sites with a median follow-up of
50.3 [34_TD$DIFF]months using predefined inclusion/exclusion criteria
per REMARK guidelines (Supplementary Fig. 1). A predefined
assay cut-off of 0.3613 was used to define metastatic assay
positivity in a blinded manner. On multivariable analysis, a
positive assay result was associatedwith an increased risk of
biochemical recurrence (HR = 1.62 [1.13–2.33]; p = 0.0092;
Table 1 – Validation of metastatic assay in the [13_TD$DIFF] Memorial Sloan Kettering Cancer Centre [14_TD$DIFF](MSKCC [15_TD$DIFF]) cohort
Biochemical recurrence Metastatic recurrence
Covariate HR 95% CI p Covariate HR 95% CI p
Multivariate model 1 Multivariate model 1
Metastatic assay 3.03 1.43–6.41 0.0040 Metastatic assay 2.53 0.67–9.54 0.1735
Gleason (3 + 4) Gleason (3 + 4) a
<7 0.38 0.10–1.37 0.1409 <7 0.00 0.00 0.9658
4 + 3 2.04 0.76–5.43 0.1579 4 + 3 22.61 2.34–218.06 0.0073
8–10 8.09 2.74–23.91 0.0002 8–10 187.79 16.52–2134.99 <0.0001
Age 0.99 0.94–1.04 0.6564 Age 0.88 0.80–0.97 0.0110
PSA 1.00 0.96–1.04 0.9857 PSA 0.94 0.89–0.98 0.0106
Multivariate model 2 Multivariate model 2
Metastatic assay 3.35 1.62–6.94 0.0012 Metastatic assay 3.95 1.15–13.53 0.0298
CAPRA-S 3.92 1.92–7.99 0.0002 CAPRA-S 3.50 1.13–10.80 0.0302
HR = hazard ratio; CI = conﬁdence intervals; PSA = prostate-speciﬁc antigen; CAPRA-S = Cancer of the Prostate Risk Assessment postsurgical.
Multivariable analysis of the MSKCC cohort for biochemical recurrence (right) and metastatic recurrence (left), p values, HRs and 95% CIs of the HR are outlined
within the table (multivariate model 1). Covariate analysis of the metastatic assay adjusting for CAPRA-S within the MSKCC cohort is also included with p
values, HRs and 95% CIs[2_TD$DIFF] of the HR are outlined (multivariate model 2).
a Absence of metastatic events in patients with Gleason score <3 + 4.
[(Fig._2)TD$FIG]
[1_TD$DIFF] ig. 2 – Validation of the metastatic assay in resections using the MSKCC in silico dataset. Kaplan–Meier survival analysis for association of the
metastatic assay at predicting (A) time to biochemical recurrence and (B) metastatic [8_TD$DIFF]recurrence in the MSKCC in silico cohort. Survival probability (%)
showed reduced progression-free survival in months of the ‘‘assay positive’’ ([9_TD$DIFF]orange) of [10_TD$DIFF]41 patients when compared with the ‘‘assay negative’’ (blue) of
[11_TD$DIFF]85 patients for biochemical and metastatic [12_TD$DIFF]disease respectively (HR = 3.76 [1.70–8.34]; p < 0.0001 and HR = 6.00 [1.90–18.91]; p = 0.0005, respectively).
HR = hazard ratio.
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Fig. 3A and Table 2) and metastatic recurrence
(HR = 3.20 [1.76–5.80]; p = 0.0001; Fig. 3B and Table 2).
Although the assaywas designed to provide information as a
dichotomous result, it was also an independent predictor of
both biochemical and metastatic recurrence when assessed
as a continuous variable in multivariate analysis
(HR = 1.16 [1.03–1.30]; p = 0.0155 and HR = 1.52 [1.24–
1.85]; p < 0.0001 [per 0.1 unit change in assay score];
Supplementary Table 15).
3.6. Comparison of the metastatic assay with clinical risk
stratification
To test assay independence from approaches used in the
clinic, we assessed its performance within risk groups
defined by GS and the CAPRA-S model in the independent
resection validation cohort. When separated by Gleason
(high-risk GS4 + 3 and low-risk GS3 + 4), themetastatic
assay identified patients at higher risk of metastatic
recurrence with an HR of 2.43 (1.14–5.17; p = 0.0036)
and HR of 5.61 (1.19–26.47; p = 0.0013) in the high- and
low-risk GS groups, respectively (Fig. 3C).
The CAPRA-S prognostic model uses PSA at presentation,
age, GS, T-stage, seminal vesicle invasion, extracapsular
extension, lymph node invasion, and surgical margins
[13]. In a multivariable analysis adjusted for CAPRA-S, both
the metastatic assay and the CAPRA-S were significantly
associated with biochemical recurrence (HR = 1.72 [1.19–
2.48]; p = 0.0042 and HR = 2.52 [1.79–3.54]; p < 0.0001)
and development of metastatic disease (HR = 2.94 [1.60–
5.40]; p = 0.0005 and HR = 4.76 [2.46–9.23]; p < 0.0001;
Table 2). Given the independence of the metastatic assay
result and CAPRA-S score, a combined model was assessed.
Patients classified within the high-risk subgroup[7_TD$DIFF] were
[(Fig._3)TD$FIG]
Fig. 3 – Validation of the metastatic assay in the retrospective independent resection validation dataset. Kaplan–Meier survival analysis for association
of the metastatic assay at predicting (A) time to biochemical recurrence and (B) metastatic [8_TD$DIFF]recurrence in the resection validation cohort. Survival
probability (%) showed reduced progression-free survival in months of the ‘‘assay positive’’ ( [9_TD$DIFF]orange) of 74 patients when compared with the ‘‘assay
negative’’ (blue) of 248 patients for biochemical and metastatic [12_TD$DIFF]disease respectively (HR = 1.76 [1.18–2.64]; p = 0.0008 and HR = 3.47 [1.70–7.07];
p < 0.0001, respectively). (C) Association of the metastatic assay at predicting metastatic [8_TD$DIFF]recurrence stratified into low-risk (GS = 3 + 4) and high-risk
(GS I 4 + 3) tumours (HR = 5.61 [1.19–26.47]; p = 0.0013 and HR = 2.43 [1.14–5.17]; p = 0.0036 respectively). GS = Gleason score; HR = hazard ratio.
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significantly associated with both biochemical and meta-
static recurrence (HR = 2.67 [1.90–3.75]; p < 0.0001 and
HR = 7.53 [4.13–13.73]; p < 0.0001, respectively), demon-
strating superiority to eithermodel alone (Fig. 4 and Table 2,
combined model).
To assess the clinical impact of the combined model of
metastatic assay plus CAPRA-S, additional performance
metrics were assessed for the metastatic [50_TD$DIFF]endpoint in the
independent resection validation cohort. As the assay was
dichotomous, the comparison of sensitivity and specificity
between themetastatic assay alone, CAPRA-S alone, and the
combined model were investigated. Whilst the sensitivity
of CAPRA-S (70.5%) was greater than that of the metastatic
assay alone (47.7%), there was an increase in sensitivity to
80.1% in the combined model. There was, however, a
decrease in specificity from 81.9% (metastatic assay) and
71.5% (CAPRA-S) to 61.1% in the combined model, which
may indicate patients who have not yet experienced
recurrence within the 50.3- [34_TD$DIFF]months median follow-up
(Supplementary Table 16).
Assessment as a continuous predictor using AUC and
decision curve analysis demonstrated an improvement in
discrimination power of metastatic events and a greater net
benefit for the combined model at a representative risk
[(Fig._4)TD$FIG]
Fig. 4 – Validation of the metastatic assay in resections using a combined model with CAPRA-S to stratify high and low risk. (A) Association of a
combined model (metastatic assay + CAPRA-S) at predicting time to biochemical recurrence of high/low-risk disease in the resection cohort. Reduced
progression-free survival in months of the ‘‘high-risk’’ subgroup ( [9_TD$DIFF]orange) of 112 patients when compared with the ‘‘low-risk’’ subgroup (blue) of
125 patients (HR = 2.67 [1.90–3.75]; p < 0.0001). (B) Association of a combined model (metastatic assay + CAPRA-S) at predicting time to metastatic
disease [8_TD$DIFF]recurrence of high/low-risk disease in the resection cohort. Reduced progression-free survival in months of the ‘‘high-risk’’ subgroup ([9_TD$DIFF]orange)
of 112 patients compared with the ‘‘low-risk’’ subgroup (blue) of 125 patients (HR = 7.53 [4.13–13.73]; p < 0.0001). CAPRA-S = Cancer of the Prostate
Risk Assessment postsurgical; HR = hazard ratio.
Table 2 – Validation of metastatic assay in the independent resection validation dataset
Biochemical recurrence Metastatic recurrence
Covariate HR 95% CI p Covariate HR 95% CI p
Multivariate model 1 Multivariate model 1
Metastatic assay 1.62 1.13–2.33 0.0092 Metastatic assay 3.20 1.76–5.80 0.0001
Gleason (3 + 4) Gleason (3 + 4)
<7 0.76 0.44–1.30 0.3224 <7 0.72 0.19–2.73 0.6358
4 + 3 1.95 1.29–2.95 0.0017 4 + 3 4.33 1.89–9.93 0.0006
8–10 2.79 1.82–4.30 <0.0001 8–10 6.85 2.92–16.04 <0.0001
Age 1.00 0.97–1.03 0.9027 Age 0.97 0.92–1.02 0.2828
PSA 1.01 1.00–1.01 0.0321 PSA 1.00 0.99–1.01 0.6423
Multivariate model 2 Multivariate model 2
Metastatic assay 1.72 1.19–2.48 0.0042 Metastatic assay 2.94 1.60–5.40 0.0005
CAPRA-S 2.52 1.79–3.54 <0.0001 CAPRA-S 4.76 2.46–9.23 <0.0001
Combined model Combined model
Metastatic assay + CAPRA-S 2.67 1.90–3.75 <0.0001 Metastatic assay + CAPRA-S 7.53 4.13–13.73 <0.0001
HR = hazard ratio; CI = conﬁdence intervals; PSA = prostate-speciﬁc antigen; CAPRA-S = Cancer of the Prostate Risk Assessment postsurgical.
Multivariable analysis of the metastatic assay in the independent resection validation cohort for biochemical recurrence (right) and metastatic [8_TD$DIFF]recurrence (left),
p values, HRs and 95% CIs of the HR are outlined within the table (multivariate model 1). Covariate analysis of the metastatic assay adjusting for CAPRA-S within
the independent resection validation cohort is also included with p values, HRs and 95% CIs of the HR outlined (multivariate model 2). Analysis from a
combined model of the metastatic assay and CAPRA-S within the independent resection validation cohort was also assessed, outlining p values, HRs, and [16_TD$DIFF]95%
CIs for biochemical and metastatic disease [8_TD$DIFF]recurrence (combined model).
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threshold of 25% (AUC = 0.80 and net benefit = 0.052),
compared with either metastatic assay (AUC = 0.71 and
net benefit = 0.035) or CAPRA-S alone (AUC = 0.76 and net
benefit = 0.021) (Supplementary Table 17 and Supplemen-
tary Fig. 6). This suggests that for patients with a 25% risk of
developing metastatic recurrence, a greater net benefit is
achieved using the metastatic assay in conjunction with
CAPRA-S. In addition, the continuous combinedmodel had a
C-index of 0.82 (0.76–0.86) comparedwith a C-index of 0.71
(0.64–0.78) for metastatic assay and a C-index of 0.73
(0.66–0.79) for CAPRA-S alone (Supplementary Table 17).
4. Discussion
The majority of early prostate cancer patients treated by
radical resection are cured. However, up to 25% of patients
develop metastatic disease within 15 [38_TD$DIFF]years [1,2]. In
surveillance for low/intermediate-risk disease, there is
concern about risks of clinical undergrading and disease
progression, with a proportion of patients needing treat-
ment within 5 [38_TD$DIFF]years [3]. This engenders clinical uncertainty
in modern practice in two key areas: firstly, in the
appropriate and safe selection of patients for active
surveillance, particularly in the Gleason 3 + 4 intermediate
group, and secondly, in patients undergoing radical local
treatment for intermediate- and higher-grade tumours,
where adjuvant locoregional and systemic treatment may
improve outcome. A test that helps select patients at a
higher risk of progression in these settings will have
significant clinical utility.
Several prognostic gene expression assays have been
developed by comparing gene expression data between
good and poor outcome patients [16–18]. In contrast, we
identified a molecular subgroup of primary prostate cancer
samples that shared biology with metastatic disease. We
developed an assay for this molecular subgroup, which
identified patients at risk of biochemical and metastatic
recurrence in three publicly available and one prospectively
collected multicentre dataset.
Consistent with the molecular subgroup representing
metastatic biology, the assay was better at predicting
metastatic [8_TD$DIFF]recurrence rather than biochemical recurrence.
The latter does not necessarily predict metastatic develop-
ment; only one-third of patients with biochemical recur-
rence develop measurable metastatic disease 8 [38_TD$DIFF]years after
resection [27]. In addition, the HR of 3.20 for metastatic
recurrence compares favourably to the reported hazard
ratios for other prognostic assays to predict metastatic
disease, with HRs ranging between 1.40 and 3.30 [16–18]. A
significant feature of assay performance was independence
from CAPRA-S, allowing the development of a combined
risk model with superior performance to either CAPRA-S or
the metastatic assay individually.
An interesting feature of the metastatic subgroup was
methylation and loss of gene expression such as OLFM4
known to inhibit metastatic processes including WNT
signalling [28]. It is therefore possible that novel therapies
aimed at reversing epigenetic silencing or targeting WNT
signalling may act against the metastatic biology in this
molecular subgroup [29]. Regarding upregulated genes in
the metastatic-subgroup, a significant proportion was
regulated by FOXM1 known to promote prostate cancer
progression [30]. Indeed, others have found increased
FOXM1 gene expression to be prognostic and have included
it in a 31-gene expression assay [16]. Interestingly only 6/70
genes in the metastatic assay overlapped with three
prognostic signatures that are entering clinical practice
(AZGP1 [18], PTTG1, TK1 and KIF11 [16], and ANO7 and
MYBPC1 [17])—Oncotype Prostate (p = 0.16), Prolaris
(p = 0.06), and Decipher (p = 0.06)—after multiple test
correction using a Benjamini–Hochberg correction, likely
reflecting the distinct approach of molecular subtyping
versus trained [50_TD$DIFF]endpoint analysis (Supplementary Fig. 7).
A potential limitation of this study is the retrospective
validation of the assay in historic datasets. Diagnostic and
surgical approaches have improved with time, which may
reduce disease recurrence. We expect, however, that the
effect of these improvements would mostly be on local
recurrence, whereas this assay has been developed to
predict metastatic disease progression, likely largely
beyond surgical control at presentation.
5. Conclusions
Wehave identified amolecular subgroup of primary prostate
cancer with metastatic capacity. We hypothesise that using
this molecular subtyping approach may improve patient
stratification considering active surveillance andmay benefit
patients with higher-risk clinically localised disease by
focusing [51_TD$DIFF]loco-regional and systemic adjuvant therapy in
those at the highest risk of regional and systemic failure.
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